Yuhan Cor­po­ra­tion to pay $325M to in-li­cense pre­clin­i­cal HER2 can­di­date

Yuhan Cor­po­ra­tion said Tues­day that it is pay­ing up to $325 mil­lion to fel­low South Ko­re­an biotech J INTS Bio to li­cense an oral non-small cell lung can­cer drug.

The deal is for JIN-A04, a pre­clin­i­cal oral ty­ro­sine ki­nase in­hibitor tar­get­ing NSCLC with HER2 ex­on 20 mu­ta­tions.

J INTS Bio said back in Feb­ru­ary that pre­clin­i­cal da­ta on the mol­e­cule would be pre­sent­ed at the Amer­i­can As­so­ci­a­tion for Can­cer Re­search’s an­nu­al meet­ing in Or­lan­do, say­ing that the mol­e­cule “showed po­tent ef­fi­ca­cy against HER2 Ex­on20 in­ser­tion mu­tant NSCLC cell lines, and in-vi­vo mouse mod­els us­ing HER2 Ex­on20 in­ser­tion mu­tant cell lines sig­nif­i­cant tu­mor re­gres­sion was demon­strat­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER